Biotech Values

[DewDiligence]

BIOD reverse merges into Albireo Ltd:

http://finance.yahoo.com/news/biodel-inc-albireo-limited-agree-000423804.html

Under the terms of the share exchange agreement, Albireo stockholders have agreed to exchange their shares of Albireo for newly issued shares of Biodel common stock. On a pro forma basis, Biodel stockholders are expected to own approximately 33%, and Albireo stockholders are expected to own approximately 67%, of the combined company…

Upon closing of the transaction, Biodel will change its name to Albireo Pharma, Inc. and plans to change its ticker symbol on the NASDAQ Capital Market to ALBO. Ron Cooper, Albireo's President and Chief Executive Officer, will become President and Chief Executive Officer of the combined company.

… Albireo is developing its lead product candidate, A4250, initially for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC), which is a life threatening, orphan liver disease that affects young children. A4250 is currently being studied in a Phase 2 clinical trial in children with cholestatic liver disease that is designed to support Albireo's planned future pivotal development in PFIC.

CC tomorrow at 8:30am ET.